ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.

Inclusion Criteria:

• You have a diagnosis of non-small cell lung cancer.
• You have received no prior chemotherapy.
• You have at least one measurable lesion.
• You have an adequate performance status.
• You are at least 18 years of age.

Exclusion Criteria:

• You have previously received chemotherapy for your lung cancer.
• You have received radiation within the last 30 days.
• You have active infection or other serious condition.
• You have brain metastasis.
• You have recently lost a significant amount of weight.